The ADHD Voices (Voices On Identity, Childhood, Ethics and Stimulants) report was published yesterday and received a significant amount of press coverage. The outcomes of this work are a 46-page report and 18-minute video, that aim to inspire a fresh public conversation about the ethics of Attention Deficit/Hyperactivity Disorder (ADHD) diagnosis and stimulant drug treatments [read the full story…]
Back in February, I blogged about a cohort study published in the New England Journal of Medicine, which concluded that ADHD drugs are not linked with an increased risk of serious cardiovascular events. The last few years has seen heated debate about the use of central nervous stimulants in children and young people. The lack [read the full story…]
A number of concerns have arisen over recent years about the safety of the various drugs used to treat ADHD (Attention Deficit Hyperactivity Disorder) in children and young adults. These central nervous system stimulants include methylphenidate, dexmethylphenidate, dextroamphetamines, amphetamine salts, atomoxetine and pemoline. Case reports have highlighted that sudden cardiac death can be brought on [read the full story…]
Attention deficit hyperactivity disorder (ADHD) is a group of behavioural symptoms that include inattentiveness, hyperactivity and impulsiveness. ADHD is often thought of as a childhood problem, but it can be a lifelong condition, and many children continue to have symptoms as a teenager and adult. It is estimated that nearly two-thirds of children with ADHD [read the full story…]
